Volcano Corp. Is Likely To Be Acquired Soon - Here Is Why Print E-mail
By Michael Kovar and Scott Matusow   
Friday, 13 June 2014 08:38
The company we believe is close to being acquired for a nice premium is Volcano Corp. (VOLC).
Read more...
 
NWBO’s Interim Data: Completely Worthless Print E-mail
By Brian Wilson - Lead Contributor   
Thursday, 12 June 2014 09:18
Yesterday, traders sent Northwest Biotherapeutics (NWBO) 11.87% higher after the company released an 8-week interim data readout  from a Phase I/II trial for the product DCVax – an immunotherapy being developed for inoperable solid tumors.
Read more...
 
Is Achillion Pharma Overextended? Print E-mail
By Brian Wilson - Lead Contributor   
Wednesday, 11 June 2014 09:12
Investors send shares of Achillion Pharmaceuticals (ACHN) ~167% higher since the start of the week after it was announced that the FDA removed the clinical hold on the HCV treatment sovaprevir.  
Read more...
 
MannKind Surges Upward Ahead of July PDUFA Print E-mail
By Brian Wilson - Lead Contributor   
Monday, 09 June 2014 09:27
It appears that MannKind (MNKD) will soon receive FDA approval for their inhalable insulin product Afrezza.
Read more...
 
Clovis Stabilizes After Big ASCO-Related Crash Print E-mail
By Brian Wilson - Lead Contributor   
Thursday, 05 June 2014 09:26
Since Friday of last week, Clovis Oncology (CLVS) is down over 25% on newly discovered safety concerns that threaten the competitive edge of its flagship drug CO-1686 against AstraZeneca's AZD9291.
Read more...
 
Progenics Pharma Poised For A Potential Price Increase Ahead Of June 11th Adcom Print E-mail
By Kyle Dennis and Scott Matusow   
Monday, 02 June 2014 20:05
Progenics is expecting a Food and Drug Administration (FDA) Advisory Committee meeting on June 11 - 12 to decide whether or not to recommend a Supplemental New Drug Application (sNDA).
Read more...
 
The IBB Likely To Move Higher Along With These Biotechs With Near Term Catalysts Print E-mail
By Scott Matusow   
Monday, 02 June 2014 19:55
Today, we list four bio pharmaceutical companies with upcoming catalysts. Typically, under normal market conditions, their stocks normally see strong price appreciation.
Read more...
 
Dendreon Continues Descent To $0 Per Share Print E-mail
By Brian Wilson - Lead Contributor   
Monday, 02 June 2014 09:33
Dendreon (DNDN) is a value trap stock that we've been warning investors about since 2012 - when the stock was trading 200-300% higher than its current value.
Read more...
 
Approval of Orexigen’s NB32 Further Threatens Obesity Drug Market Print E-mail
By Brian Wilson - Lead Contributor   
Tuesday, 27 May 2014 07:32
Last week, we discussed the broken prospects of Arena (ARNA) and Vivus (VVUS) – the companies that developed the two FDA-approved obesity drugs on the market today (Belviq and Qsymia).
Read more...
 
Could Placental Cell Therapy be a Preemptive Approach to Protecting Women from Disabling Strokes? Print E-mail
By William R. Prather RPh, MD Sr. VP Corporate Development Pluristem Therapeutics, Inc.   
Saturday, 24 May 2014 17:33
In February, 2014 a coordinated effort between the American Heart Association and the American Stroke Association resulted in the publishing in the clinical journal Stroke the first-ever guidelines for the prevention of stroke in women.
Read more...
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 13 of 56

Newsletter